Only for a while, and the while is shorter than a monthly figure makes it feel. At national retail prices, cumulative spending on some of these drugs passes the one-off cost of sleeve gastrectomy in about nine months and gastric bypass in under a year [1]. Measured a different way — what insured patients actually paid over three years — semaglutide came to $7,752 out of pocket against $5,980 for a sleeve [2].
A monthly figure is designed to feel small, and the way to test that feeling is to compare it against something charged once. That is a harder version of the year-long sums in what a GLP-1 actually costs.
What the break-even analysis did
Researchers took average 2023 national retail prices for these drugs, and took surgical cost estimates adjusted for inflation. They then plotted cumulative medication spending against the flat cost of each operation to find where the lines cross.
For some of the drugs the crossing arrives fast. An older drug in the same class, priced lowest of those compared, takes around a year and a half to become the more expensive choice.
What was actually billed, and to whom
A separate analysis followed insured patients with diabetes and obesity for three years and compared what each route cost them. Out-of-pocket spending was $7,752 on semaglutide against $5,980 on sleeve gastrectomy, while total spending across the health system barely differed between the two.
So the drug costs the patient more and the payer about the same, which is a different result from the one either side usually quotes. That split is set out in the drug costs you more and the system the same, and it is the reason a household budget and a plan formulary reach opposite conclusions from one dataset.
What it costs here instead
Across the 404 injected semaglutide figures recorded on this roster, the median billed rate is $179 a month, read September 2026 — $2,148 for a year and $6,444 across three. That is the line this comparison would be drawn against for a reader buying compounded rather than branded, and it rises far more slowly than the retail one the paper used.
The authors name two things the arithmetic cannot capture. These drugs take time to reach full effect, so cost accumulates before benefit does, and weight tends to return after stopping, which is the finding in what stopping costs. A treatment that has to continue indefinitely has no natural point at which the spending stops.
There is a third option on the same axis
Endoscopic sleeve gastroplasty is neither a drug nor a full operation, and one real-world cohort compared it against oral semaglutide directly [3]. At six months the procedure led, 12.72% against 8.67%. At twelve months it was 11.92% against 10.91%, and the difference had gone.
A procedure charges once and a drug charges monthly. A result that converges by month twelve therefore changes the cost comparison more than it changes the clinical one, and the cohort that measured it is worth reading before either is priced.
What the comparison is not
It is not a claim that the options are equivalent. Surgery is irreversible, carries operative risk, and produces larger and more durable weight loss than any drug in this class. The drugs are reversible, carry no operative risk, and stop working when they stop. Those differences are the decision, and cost is one input to it.
The authors are explicit about their own limits: real-world costs vary with insurance, long-term costs and comorbidities were not fully evaluated, and patient preference carries value no model can price. What the papers supply is the shape of the trade, and the shape is that a recurring charge catches a one-off one faster than most people expect. Where the two sit on outcomes rather than on price is in what works best outside a trial, and the sequencing question is in before or after the operation.